who owns the patent for retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation TBPN's Video on X

Its signature GLP-1 product combines tirzepatide with glycine and B12 (cyanocobalamin)

Data Source: 15% nationally representative sample of Medicare fee-for-service (FFS) administrative claims data, encompassing hospitalization claims (Part A), outpatient services (Part B), and prescription drug records (Part D)

Contrastingly, no statistically significant signal values were observed in other age groups, including younger adults, adults, and the elderly, based on both ROR and EBGM05

Semaglutide is a GLP-1 receptor agonist already approved separately as Ozempic, Wegovy, and Rybelsus depending on formulation and indication

Key findings: Elevated CSF GFAP and CSF CHI3L1 levels were independently associated with confirmed disability progression at 1 year